Developer docs
API playgroundTry for free, no card

Search company profiles

RenalSense

Full company profile

uuid0002jgc

Namestring
RenalSense
Websiteurl
renalsense.com
Company typeenum
Private
Founded yearint
2010
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersJerusalem, Israel
HQ citystring
Jerusalem
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Keyword5 values
acute kidney injury monitoring, critical care diagnostics, real-time renal monitoring, ICU medical devices, AKI detection platform
Industry3 codes
PRIMARYHLAHAKAJ
Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status)
SECONDARYHLAKAHAI
Acute Kidney Injury (AKI) & Hospital Nephrology (Inpatient Consults)
SECONDARYHLAKAHAN
Critical Care Nephrology (ICU/CRRT Services)
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Critical Care Medical Diagnostics
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

RenalSense develops a real-time diagnostic platform for the detection, prevention, and management of Acute Kidney Injury (AKI) in critical care settings. The platform is deployed in intensive care units (ICUs) to continuously monitor kidney function and enable early clinical intervention.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Real-Time AKI Diagnostic Platform for Critical Care
CategoryCritical Care Medical Diagnostics
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developed NephroCheck, the leading FDA-cleared AKI biomarker test, now owned by bioMérieux. Direct competitor in the AKI diagnostics category, addressing the same ICU clinical problem with a biomarker rather than a real-time device approach.

TypeDirect peer
Description

Developed the Accuryn system, a real-time urine output monitoring device for ICU AKI prediction — the closest functional analog to RenalSense's real-time platform. Now part of Medtronic's patient monitoring portfolio.

TypeDirect peer
Description

Commercializes The NGAL Test for early AKI detection. Competes in the same AKI diagnostic category via biomarker-based testing for critically ill patients.

TypeEmerging player
Description

Developer of penKid (proenkephalin), an emerging blood-based biomarker for real-time AKI risk assessment. Competes with RenalSense in delivering earlier AKI signals in critical care.

TypeBroad incumbent
Description

Global in vitro diagnostics leader and parent of Astute Medical/NephroCheck. A dominant incumbent in the renal diagnostic space with established hospital sales channels RenalSense must contend with.

TypeBroad incumbent
Description

Global medtech incumbent with the Potrero/Accuryn AKI monitoring asset plus a broad critical care portfolio. Competes on hospital formulary, evidence generation, and integrated ICU platforms.

TypeBroad incumbent
Description

Critical care monitoring leader with the FloTrac/HemoSphere platforms for hemodynamically compromised ICU patients — adjacent to AKI risk monitoring and a potential integrated competitor in the ICU.

TypeBroad incumbent
Description

World's largest dialysis services and products company, with deep nephrology relationships and growing interest in remote/AKI monitoring. Sets the competitive bar for renal care commercialization at scale.

TypeBroad incumbent
Description

Diversified medtech with a renal care franchise (dialysis machines, CRRT, peritoneal dialysis) and active interest in earlier-stage kidney injury management in the ICU.

TypeEmerging player
Description

Developer of the Tablo hemodialysis system used in both hospital and home settings. Comparable as a renal-focused technology challenger attempting to disrupt established renal care workflows.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RenalSense

Critical Care Medical Diagnosticsrenalsense.com

RenalSense firmographics

Firmographics
Name
RenalSense
Website
https://renalsense.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

RenalSense industry classification

Industry
Product category
Critical Care Medical Diagnostics
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAKAJ
Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status)
SECONDARYHLAKAHAI
Acute Kidney Injury (AKI) & Hospital Nephrology (Inpatient Consults)
SECONDARYHLAKAHAN
Critical Care Nephrology (ICU/CRRT Services)

Keywords

  • Acute kidney injury monitoring
  • Critical care diagnostics
  • Real-time renal monitoring
  • ICU medical devices
  • AKI detection platform

Where RenalSense is headquartered

Location

Headquarters

HQ city
Jerusalem
HQ country
Israel
HQ region
Middle East

Markets served

RenalSense business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

RenalSense product offering

Product offering

Core offering

RenalSense develops a real-time diagnostic platform for the detection, prevention, and management of Acute Kidney Injury (AKI) in critical care settings. The platform is deployed in intensive care units (ICUs) to continuously monitor kidney function and enable early clinical intervention.

Differentiator

Problem solved

Functional benefit

Products and services

  • Real-Time AKI Diagnostic Platform for Critical Care

Companies that use RenalSense

Customer profile

Ideal customer profiles1 record

RenalSense technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

RenalSense partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

RenalSense competitors and assessment

Company assessment

Direct peers

  • Astute Medical (a bioMérieux company): Developed NephroCheck, the leading FDA-cleared AKI biomarker test, now owned by bioMérieux. Direct competitor in the AKI diagnostics category, addressing the same ICU clinical problem with a biomarker rather than a real-time device approach.
  • Potrero Medical (acquired by Medtronic): Developed the Accuryn system, a real-time urine output monitoring device for ICU AKI prediction — the closest functional analog to RenalSense's real-time platform. Now part of Medtronic's patient monitoring portfolio.
  • BioPorto Diagnostics: Commercializes The NGAL Test for early AKI detection. Competes in the same AKI diagnostic category via biomarker-based testing for critically ill patients.

Emerging players

  • Sphingotec: Developer of penKid (proenkephalin), an emerging blood-based biomarker for real-time AKI risk assessment. Competes with RenalSense in delivering earlier AKI signals in critical care.
  • Outset Medical: Developer of the Tablo hemodialysis system used in both hospital and home settings. Comparable as a renal-focused technology challenger attempting to disrupt established renal care workflows.

Broad incumbents

  • bioMérieux: Global in vitro diagnostics leader and parent of Astute Medical/NephroCheck. A dominant incumbent in the renal diagnostic space with established hospital sales channels RenalSense must contend with.
  • Medtronic: Global medtech incumbent with the Potrero/Accuryn AKI monitoring asset plus a broad critical care portfolio. Competes on hospital formulary, evidence generation, and integrated ICU platforms.
  • Edwards Lifesciences: Critical care monitoring leader with the FloTrac/HemoSphere platforms for hemodynamically compromised ICU patients — adjacent to AKI risk monitoring and a potential integrated competitor in the ICU.
  • Fresenius Medical Care: World's largest dialysis services and products company, with deep nephrology relationships and growing interest in remote/AKI monitoring. Sets the competitive bar for renal care commercialization at scale.
  • Baxter International: Diversified medtech with a renal care franchise (dialysis machines, CRRT, peritoneal dialysis) and active interest in earlier-stage kidney injury management in the ICU.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

RenalSense social profiles

Digital presence

RenalSense financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RenalSense leadership team

Management profile

Number of profiles

Profiles1 record

RenalSense funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RenalSense M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RenalSense

What does RenalSense do?

RenalSense develops a real-time diagnostic platform for the detection, prevention, and management of Acute Kidney Injury (AKI) in critical care settings. The platform is deployed in intensive care units (ICUs) to continuously monitor kidney function and enable early clinical intervention.

Is RenalSense a public or private company?

RenalSense is a private company. It is classified as venture growth investor backed and is currently operating.

When was RenalSense founded?

RenalSense was founded in 2010. It employs 1 to 10 people.

Where is RenalSense based?

RenalSense is headquartered in Jerusalem, Israel, in the Middle East region.

Who are RenalSense's main competitors?

Direct peers on record are Astute Medical (a bioMérieux company), Potrero Medical (acquired by Medtronic) and BioPorto Diagnostics. Emerging players are Sphingotec and Outset Medical. Broad incumbents are bioMérieux, Medtronic, Edwards Lifesciences, Fresenius Medical Care and Baxter International.

Does RenalSense have an API?

No public API is recorded for RenalSense.

What industry is RenalSense in?

RenalSense's product category is Critical Care Medical Diagnostics. Its primary akta.pro industry code is HLAHAKAJ, Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status), with a secondary code of HLAKAHAI, Acute Kidney Injury (AKI) & Hospital Nephrology (Inpatient Consults). Its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireTechnavio's Renal Biomarkers Market Research Report Highlights the Key Findings in the Area of Vendor Landscape, Key Market Segments, Regions, and Latest Trends and DriversTechnavio's market research report projects the global renal biomarkers market to grow by USD 507.23 million from 2021 to 2026, decelerating at a compound annual growth rate of 7.40%, driven by rising prevalence of chronic kidney diseases. North America is expected to account for 47% of market share growth, with the US, Germany, UK, Canada, and France identified as key consumer countries. The report profiles Abbott Laboratories, bioMerieux SA, BioPorto AS, F. Hoffmann-La Roche Ltd., IQVIA Holdings Inc., Randox Laboratories Ltd., RenalSense Ltd., Siemens AG, SphingoTec GmbH, and Thermo Fisher Scientific Inc. as leading vendors in this fragmented market.PR NewswireRenalSense raises $14M Series A Funding to Bolster Global Commercialization and Expand its Product LineRenalSense raised $14M in Series A funding led by BlueRed Partners Fund to expand global commercialization of its Clarity RMS renal monitoring system. The company will validate the product in additional clinical settings and develop next-generation sensor-based products. It has installed the system in tens of operating rooms and ICUs across the US, Europe, and Israel.PR NewswireRenalSense raises $14M Series A Funding to Bolster Global Commercialization and Expand its Product LineRenalSense, a Jerusalem-based medical device company specializing in real-time renal diagnostics, has raised $14 million in Series A funding led by BlueRed Partners Fund (Singapore), with participation from healthcare-focused family offices and existing shareholders. The funding will support global commercialization of its Clarity RMS critical care monitoring system, expand clinical validation into cardiology and anesthesia settings, and advance next-generation sensor-based products. The company has FDA clearance and CE-certification with installations in leading medical centers across the US, Europe, and Israel.The RegisterFormer CTO of Intel RealSense joins car tech company LuminarAnders Grunnet-Jepsen, former CTO of Intel's RealSense group, joined Luminar as head of advanced development. Intel is winding down RealSense, with most products ending sales in February 2022, while Stereo Cameras remain available.CRNWhy Pat Gelsinger Decided To Wind Down Intel’s RealSense Unit: ExclusiveIntel CEO Pat Gelsinger said he will wind down the RealSense computer vision division because it does not fit the company's six core business units. He will rationalize all assets against those units, including data center, client computing, graphics, networking, foundry, and autonomous driving. The company will honor customer commitments and use the expertise to support core businesses.WebProNewsRIP RealSense: Intel Shutting Down Camera and Sensor DivisionIntel is shutting down its RealSense division, which develops AI-driven cameras for robotics, facial recognition, and digital signage. The decision follows poor sales and lackluster adoption, and the company will transition its computer vision talent and products to support its core semiconductor business and IDM 2.0 strategy.EngadgetIntel is giving up on its AI-powered RealSense camerasIntel is winding down its AI-powered RealSense cameras, transferring the team and computer vision tech to support its core chip businesses. The move follows the departure of team leader Sagi Ben Moshe, and CEO Pat Gelsinger aims to concentrate resources on design and manufacturing.PR NewswireRenalSense Announces Distribution Agreement in Mainland China with GlorywayRenalSense announced a distribution agreement with Gloryway to market and manufacture its Clarity RMS critical care monitoring system in mainland China. The partnership aims to enhance ICU capabilities for early detection of Acute Kidney Injury, addressing a significant healthcare need driven by an aging population.PR NewswireRenalSense Announces Distribution Agreement in Israel with MedtechnicaRenalSense announced a distribution agreement with Medtechnica, Israel's largest medical equipment distributor, to market its Clarity RMS critical care monitoring system to hospitals throughout Israel. Medtechnica will leverage its established distribution network to expand renal monitoring capabilities in Israeli intensive care units, where the system is already installed at institutions such as Assuta Ashdod Medical Center. The company stated it is in discussions with additional partners for distribution agreements in other key markets.